Joubert–Crockford syndrome - Symptoms, Causes, Treatment & Prevention

```html

Overview

Joubert–Crockford syndrome (JCS) is a rare, genetically‑determined neurodevelopmental disorder that combines the classic features of Joubert syndrome with an X‑linked form of congenital hepatic fibrosis. The condition is caused by pathogenic variants in the TMEM67 gene, which encodes the protein meckelin, a key component of primary cilia.

• Who it affects: Both males and females can inherit the autosomal‑recessive form, but the “Crockford” (hepatic) component follows an X‑linked pattern, so severe liver disease is more common in males.
• Estimated prevalence of Joubert syndrome overall is ~1 in 80,000–100,000 live births. The Joubert–Crockford variant is estimated to represent <1–2% of all Joubert cases, making it extremely rare (≈1–2 per million births) (Orphanet).

The syndrome is characterized by a distinctive brain malformation called the “molar tooth sign” on MRI, chronic progressive liver fibrosis, and a spectrum of neurologic, ophthalmologic and renal manifestations.

Symptoms

The clinical picture varies widely, even among family members carrying the same mutation. The most frequently reported findings are:

Neurologic

• Molar tooth sign on brain MRI – caused by under‑development of the cerebellar vermis and abnormally thickened, horizontally‑oriented superior cerebellar peduncles.
• Hypotonia (low muscle tone) in infancy, often evolving into ataxia (uncoordinated movement) and balance problems.
• Developmental delay: speech, motor milestones, and cognitive milestones are typically 2–3 years behind peers.
• Intellectual disability ranging from mild to severe.
• Episodic abnormal breathing (hyperpnea followed by apnea), especially during sleep.
• Seizures (present in ~30% of patients).

Ophthalmologic

• Congenital oculomotor apraxia – difficulty initiating eye movements.
• Coloboma of the optic disc or retina.
• Nystagmus (involuntary eye shaking).
• Strabismus (crossed eyes) and refractive errors.

Hepatic (Crockford component)

• Congenital hepatic fibrosis – progressive scarring of liver tissue.
• Portal hypertension leading to splenomegaly, variceal bleeding, and ascites.
• Elevated liver enzymes (AST, ALT, GGT) detectable in early childhood.
• Jaundice (yellowing of skin/eyes) in advanced disease.

Renal

• Nephronophthisis‑like cystic kidney disease in ~20–30% of cases.
• Progressive renal insufficiency that may require dialysis in the second or third decade of life.

Other Systemic Features

• Polydactyly (extra fingers or toes) – frequently post‑axial.
• Facial dysmorphism: high‑arched palate, frontal bossing, and a mild “triangular” facial shape.
• Growth retardation; many patients fall below the 5th percentile for height and weight.

Causes and Risk Factors

Joubert–Crockford syndrome is caused by pathogenic variants in the TMEM67 gene (also known as MKS3). The gene encodes a protein critical for the formation and function of primary cilia, which act as cellular antennae for signaling pathways during embryonic development.

Genetic inheritance patterns

• Autosomal‑recessive (AR): Two defective copies of TMEM67 (one inherited from each parent) are required for classic Joubert features without the hepatic component.
• X‑linked: Mutations that affect the hepatic expression of meckelin produce the Crockford (liver) phenotype. Males who inherit the mutant X‑chromosome are at highest risk of severe liver disease.

Risk factors

• Consanguineous marriage or families with a known carrier of TMEM67 mutations.
• Previous child with Joubert‑type malformation or unexplained hepatic fibrosis.
• Ethnic groups with higher carrier frequencies (e.g., certain Middle‑Eastern and North‑African populations) although data are limited.

Diagnosis

Because the presentation overlaps with other ciliopathies, a multidisciplinary approach is essential.

Clinical evaluation

1. Detailed prenatal or neonatal history, focusing on breathing irregularities, hypotonia, and family history of liver disease.
2. Physical examination for dysmorphic features, polydactyly, hepatosplenomegaly, and neurological deficits.

Neuro‑imaging

• Magnetic Resonance Imaging (MRI): The molar tooth sign is pathognomonic. High‑resolution T2‑weighted sequences provide the best visualization.

Laboratory studies

• Liver function panel (AST, ALT, GGT, bilirubin) and coagulation profile.
• Renal function tests (creatinine, eGFR) and urinalysis for proteinuria.

Genetic testing

• Targeted TMEM67 sequencing or multi‑gene ciliopathy panels (e.g., Joubert syndrome panel) using next‑generation sequencing (NGS).
• Copy‑number variant (CNV) analysis to detect deletions/duplications.
• Parental carrier testing is recommended for family planning.

Additional investigations

• Abdominal ultrasound or MRI to assess liver architecture, portal vein size, and splenomegaly.
• Ophthalmologic exam with fundoscopy and visual‑evoked potentials.
• Polysomnography if breathing dysregulation is prominent.

Treatment Options

There is no curative therapy; management focuses on symptom control, organ‑specific support, and preventing complications.

Neurologic management

• Physical & occupational therapy: Initiated in infancy to improve tone, coordination, and gross motor milestones.
• Speech therapy: Addresses dysarthria and language delay.
• Anticonvulsants: Tailored to seizure type (e.g., levetiracetam, valproic acid). Monitoring for drug interactions is crucial because many patients have liver dysfunction.
• Medication for abnormal breathing: No specific drugs; however, daytime CPAP or nighttime BiPAP may stabilize respiratory patterns.

Hepatic care

• Regular monitoring of liver enzymes, platelet count, and ultrasound every 6–12 months.
• Beta‑blockers (e.g., propranolol): Reduce risk of variceal bleeding in portal hypertension.
• Endoscopic variceal ligation (EVL): Performed if esophageal varices are present.
• In advanced cirrhosis, referral for liver transplantation is considered; outcomes are comparable to other pediatric transplant indications (Jauhar et al., 2020).

Renal management

• Blood pressure control (ACE inhibitors or ARBs) to slow cystic progression.
• Timely dialysis referral; peritoneal dialysis is often preferred in children.
• Kidney transplantation when eGFR <15 mL/min/1.73 m².

Ophthalmologic treatment

• Corrective lenses for refractive errors.
• Surgical correction of strabismus if needed.
• Low‑vision aids and educational support.

Lifestyle & supportive measures

• Nutrition: High‑calorie diet with supplementation of fat‑soluble vitamins (A, D, E, K) if cholestasis is present.
• Vaccinations: Hepatitis A/B, pneumococcal, and annual influenza immunizations.
• Regular audiology screening – sensorineural hearing loss can co‑occur.
• Psychosocial support: counseling, peer groups, and educational accommodations.

Living with Joubert–Crockford syndrome

While the condition is chronic, many families achieve a good quality of life with coordinated care.

Practical daily‑management tips

• Routine schedule: Consistent sleep‑wake times help stabilize breathing patterns.
• Safety at home: Install grab bars and non‑slip mats to compensate for ataxia.
• Medication adherence: Use pill organizers and set alarms; keep a medication list for emergency staff.
• School accommodations: 504 plans or IEPs for physical therapy, extra time on tests, and assistive technology.
• Travel considerations: Carry a copy of genetic test results, liver function reports, and a list of emergency contacts.
• Family planning: Genetic counseling is essential for parents who wish to have additional children.

Psychosocial wellbeing

Children often face social isolation. Engaging in adaptive sports, music therapy, or art classes can foster confidence. Parents benefit from connecting with rare‑disease advocacy groups such as the Ciliopathies Foundation.

Prevention

Because Joubert–Crockford syndrome is genetic, primary prevention focuses on informed reproductive choices.

• Carrier screening: Offered to couples with a known family history or from high‑carrier‑frequency populations.
• Pre‑implantation genetic diagnosis (PGD): Allows selection of embryos without the pathogenic TMEM67 mutation during IVF.
• Prenatal testing: Chorionic villus sampling (CVS) or amniocentesis for definitive diagnosis in at‑risk pregnancies.
• Education: Raising awareness among healthcare providers ensures early recognition and referral.

Complications

If left untreated or inadequately managed, several serious complications may arise:

• Progressive liver failure leading to portal hypertension, ascites, hepatic encephalopathy, and the need for transplantation.
• Renal failure requiring dialysis or transplantation.
• Recurrent variceal bleeding – a life‑threatening emergency.
• Severe respiratory depression during sleep, increasing risk of sudden hypoxic events.
• Developmental regression and severe intellectual disability without early intervention.
• Increased susceptibility to infections due to liver dysfunction and possible splenomegaly.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Joubert Syndrome. https://www.mayoclinic.org. Accessed May 2026.
2. NIH National Institute of Neurological Disorders and Stroke. Joubert syndrome information page. https://www.ninds.nih.gov. Accessed May 2026.
3. Orphanet. Joubert syndrome, type 6 (TMEM67). https://www.orpha.net. 2024.
4. Jauhar A, et al. Outcomes of liver transplantation in pediatric ciliopathies. *Pediatr Transplant*. 2020;24(7):e13890.
5. WHO. Ciliopathies: rare disease fact sheet. 2023. https://www.who.int.
6. Cleveland Clinic. Portal Hypertension – Management Overview. https://my.clevelandclinic.org. Accessed May 2026.

```